Publication date: Oct 01, 2024
Nicotinamide adenine dinucleotide (NAD) depletion has been postulated as a contributor to the severity of COVID-19; however, no study has prospectively characterized NAD and its metabolites in relation to disease severity in patients with COVID-19. We measured NAD and its metabolites in 56 hospitalized patients with COVID-19 and in two control groups without COVID-19: (1) 31 age- and sex-matched adults with comorbidities, and (2) 30 adults without comorbidities. Blood NAD concentrations in COVID-19 group were only slightly lower than in the control groups (p
| Concepts | Keywords |
|---|---|
| Depletion | 1‐methylnicotinamide |
| Dinucleotide | 2PY |
| Hospitalized | NAD+ metabolites |
| Sex | NAD+ turnover |
| nicotinamide | |
| SARS‐CoV‐2 infection |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Nadide |
| disease | MESH | COVID-19 |
| disease | IDO | blood |
| disease | MESH | Long Covid |
| drug | DRUGBANK | Nicotinamide |
| disease | MESH | infection |
Original Article
(Visited 2 times, 1 visits today)